IntroductionDatamonitor forecasts the neuropathic pain market to more than double in value from 2008 to total $5.2 billion by 2018 across the seven major markets (US, Japan, and the 5EU [France, Germany, Italy, Spain and the UK]). Although the US will provide the greatest increase in value over this period, Japan and the 5EU markets will post double-digit compound annual growth rates.ScopeStrategic analysis of the likely impact that recent events, such as regulatory decisions, will have on the future neuropathic pain marketNeuropathic pain-specific prescription sales data analysis across the seven major markets.
http://www.reportbuyer.com/
Sales forecasts for key brands (Lyrica, Lidoderm, and Cymbalta), generics, and key pipeline agents across the seven major markets to 2018Key conclusions supported by key opinion leader commentsHighlightsEli Lilly/Boehringer Ingelheim's Cymbalta (duloxetine)
Although the risk of non-approval is high, Datamonitor believes there is a convincing rationale for ralfinamide's novel mechanism for providing pain relief. By better quantifying the potential of the neuropathic low back pain target population, Datamonitor has substantially upgraded its neuropathic pain-specific forecast of the drug.Two extended-release gabapentin reformulationsXenoPort/
Solzira to achieve peak sales of almost $400m by 2018, double that for DM-1796.Reasons to PurchaseQuantify the current and future size of the neuropathic pain market.Assess the impact of recent and anticipated events (patent expiries, new product launches, regulatory approval) on the neuropathic pain market.Understand the country-specific impact of key events in the neuropathic pain market during the forecast period 2009 to 2018.
Forecast Insight: Neuropathic Pain - Brighter future for pipeline drugs while current brands downgraded: published 12/12/2009 is available at:
http://www.reportbuyer.com/
